Capricor Therapeutics Dividend
Dividend criteria checks 0/6
Capricor Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$0.71 |
| Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up
May 08
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet
Apr 19We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
Apr 16Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues
Feb 03Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?
Dec 13Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
Aug 13A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Nov 03Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03
Aug 10Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth
Feb 01We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth
Oct 14Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result
Sep 25Capricor Therapeutics slumps 9% on $75M stock offering
Jun 21Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans
May 16When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?
Mar 13Capricor signs intellectual property license for COVID-19 serology test platform
Feb 01Capricor and Lonza tie up in DMD development
Jan 12Dosing underway in Capricor Therapeutics' mid-stage CAP-1002 study in COVID-19
Nov 24Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if CAPR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CAPR's dividend payments have been increasing.
Dividend Yield vs Market
| Capricor Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (CAPR) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Biotechs) | 2.9% |
| Analyst forecast in 3 Years (CAPR) | n/a |
Notable Dividend: Unable to evaluate CAPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CAPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate CAPR's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CAPR has not reported any payouts.